



## **INDICATIONS AND USAGE**

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

## **CONTRAINDICATIONS**

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

## **PRECAUTIONS**

### **General**

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

### **Pregnancy**

### **Teratogenic Effects Category C**

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

### **Nursing Mothers**

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

### **Pediatric Use**

See **DOSAGE AND ADMINISTRATION**.

## **ADVERSE REACTIONS**

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See **PRECAUTIONS: General**).

*Gastrointestinal:* Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

*Dermatologic:* Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

*Other:* Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

## **OVERDOSAGE**

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see **CLINICAL PHARMACOLOGY, Pharmacokinetics**).

## **DOSAGE AND ADMINISTRATION**

**INFANTS:** 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

**NOTE:** Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

**CHILDREN AND ADULTS:** 4-6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of *Candida albicans*.

## **HOW SUPPLIED**

Nystatin Oral Suspension, USP, 100,000 USP Nystatin Units per mL, is available as a cherry-mint flavored, yellow, ready-to-use suspension.

60 mL bottles with a 1 mL calibrated dropper  
(NDC: 72162-2645-6) and 1 Pint  
(473 mL) bottles (NDC: 72162-2645-2)

Repackaged/Relabeled by:  
Bryant Ranch Prepack  
Burbank, CA 91504

## **SHAKE WELL BEFORE USE**

### **Storage**

Store at 20° - 25°C (68° - 77°F); excursions permitted between 15° - 30°C (59° - 86°F) [see USP Controlled Room Temperature]. AVOID FREEZING.

**PHARMACIST:** Dispense in a tight light-resistant container as defined in USP.

Manufactured for:

**Kanchan Healthcare Inc**

1 Gatehall Drive; Suite No. 202  
Parsippany, NJ 07054 USA

Toll Free Number: 833-845-2624

Rev: 06/2025

# Nystatin 100000 U/mL Suspension



Each mL contains: 100,000 units Nystatin USP in a vehicle containing sucrose, disodium edetate, sodium benzoate, sodium hexametaphosphate, dibasic sodium phosphate heptahydrate, monobasic sodium phosphate monohydrate, glycerin, cherry flavor, peppermint oil with methylparaben and propylparaben as preservatives.

Store at 20°-25°C (68°-77°F); excursions permitted between 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Avoid Freezing.

Dispense in a tight light-resistant container as defined in the USP. Shake well before using. Cherry/Mint Flavored.

With calibrated dropper. Before dispensing, replace cap with Safety cap dropper. Warnings: Keep this and all drugs out of reach of children.



In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.

NDC 72162-2645-6

## Nystatin Oral Suspension, USP

100,000 units per mL



Rebanded by:  
Bryant Ranch Prepack, Inc.  
Burbank, CA 91504 USA

Rx only  
Net: 60 mL  
Manufactured by:  
AptaPharma Inc.



**Usual Dosage: For Infants: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).**

**Usual Dosage: For Children and Adults: Scan Package Insert QR Code for full prescribing information.**

**NYSTATIN**

nystatin suspension

## Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:72162-2645(NDC:85742-013)
<b>Route of Administration</b>	ORAL		

## Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
NYSTATIN (UNII: BDF1O1C72E) (NYSTATIN - UNII:BDF1O1C72E)	NYSTATIN	100000 U in 1 mL

## Inactive Ingredients

Ingredient Name	Strength
EDETATE DISODIUM (UNII: 7FLD91C86K)	
SODIUM BENZOATE (UNII: OJ245FE5EU)	
HEXASODIUM HEXAMETAPHOSPHATE (UNII: N40N91DW96)	
SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE (UNII: 70WT22SF4B)	
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)	
GLYCERIN (UNII: PDC6A3C0OX)	
METHYLPARABEN (UNII: A2I8C7HI9T)	
PROPYLPARABEN (UNII: Z8IX2SC1OH)	
SUCROSE (UNII: C151H8M554)	
PEPPERMINT OIL (UNII: AV092KU4JH)	

## Product Characteristics

<b>Color</b>	yellow	<b>Score</b>	
<b>Shape</b>		<b>Size</b>	
<b>Flavor</b>	CHERRY (MINT)	<b>Imprint Code</b>	
<b>Contains</b>			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:72162-2645-2	473 mL in 1 BOTTLE; Type 0: Not a Combination Product	05/11/2026	
2	NDC:72162-2645-6	1 in 1 CARTON	05/11/2026	
2		60 mL in 1 BOTTLE; Type 0: Not a Combination Product		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
--------------------	--	----------------------	--------------------

ANDA	ANDA062832	08/14/2020	
------	------------	------------	--

**Labeler** - Bryant Ranch Prepack (171714327)

**Registrant** - Bryant Ranch Prepack (171714327)

**Establishment**

Name	Address	ID/FEI	Business Operations
Bryant Ranch Prepack		171714327	REPACK(72162-2645) , RELABEL(72162-2645)

Revised: 5/2026

Bryant Ranch Prepack